PPD increases stake in small molecule discovery company X-Chem citing Big Pharma relationships

By Zachary Brennan

- Last updated on GMT

PPD increases stake in small molecule discovery company X-Chem

Related tags Pharmacology

CRO PPD has exercised its option to acquire the remaining minority ownership interest of X-Chem for an undisclosed sum. X-Chem will continue to operate as a small molecule discovery company with its entire existing staff and management team. 

Back in October 2010, PPD acquired a controlling interest in X-Chem, along with the right to purchase the remaining interest on or before October 31, 2014.

PPD says that its decision to acquire the remaining minority interest in X-Chem is based on “the successful business model that X-Chem has built and the growing interest by pharmaceutical firms to gain access to X-Chem’s proprietary small molecule discovery technology​.”

Four years ago, PPD made a strategic decision to invest in X-Chem, based on their highly innovative drug discovery engine​,” David Simmons, chairman and CEO of PPD said.

X-Chem has demonstrated the value of its technology through establishment of an increasing number of relationships with major pharmaceutical and biotechnology companies, along with academic centers. Through these relationships, X-Chem has emerged as one of the top small molecule drug discovery companies in the biotechnology industry.​”

X-Chem has established partnerships with Roche, AstraZeneca, Bayer, Pfizer, and two other unnamed major pharma companies since 2010, as well as several biotechnology companies and top tier academic institutions.

In its work with partners, the company uses a proprietary DNA-encoded small molecule library with more than 100bn distinct compounds to help generate novel drugs against dozens of validated targets.

CEO and founder of X-Chem Richard Wagner added: “We have enjoyed a highly productive and collaborative relationship with PPD to date and share a belief in the potential of X-Chem to transform drug discovery through broad application of our technology to a wide spectrum of targets and therapeutic areas. We look forward to additional success for our two companies and the patient communities we ultimately aspire to help​.”

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers